- English News

12/21/2011 - Multaq (Dronedarone) reduces the risk of cardiovascular hospitalization in patients with paroxysmal, persistent atrial fibrillation (AF) or atrial flutter (AFL), but it may also cause serious cardiovascular problems, even death, warned the U.S. Food and Drug Administration (FDA).

"Healthcare professionals should not prescribe Multaq to patients with Permanent Atrial Fibrillation who cannot or will not be converted into normal sinus rhythm (permanent AF), because Multaq doubles the rate of cardiovascular death, stroke, and heart failure in such patients," the warning said as quoted by media reports Wednesday.

Based on data collected during a clinical trial study, it could be concluded that higher rate of cardiovascular cases occurred within the group of patients treated with Multaq as compared with the trail group given placebo. Therefore, FDA said, it decided to stop the trail aso as to dimminish the possibility of increasing heart failure caused by the drug.

In chemistry concepts, dronedarone is benzofuran which is described as a derivative related to amiodarone and its usage should be limited for its toxicity caused by high iodine content.

Multaq Side Effects Lawsuit

If you or a loved one have been injured as a result of Multaq side effects such as liver failure, liver damage, heart attack, stroke, or other Multaq cardiovascular side effects you may be entitled to compensation. Contact our Multaq lawyers to find out if you qualify for a multaq-injury lawsuit Fill out the free Multaq case evaluation form on this page or call us toll-free at: 1.800.856.6405.